SEPTERNA INC

Third Rock Ventures’ fresh Rule‑10b5‑1 buys reveal strong insider confidence in Septerna’s GPCR pipeline, signaling potential upside as key clinical milestones approach.

RA Capital’s sale of Septerna shares signals a portfolio shift, not a loss‑taking move, underscoring investor confidence as the biotech gears toward Phase 2 milestones.

Septerna insider trading: Bhatt Elizabeth’s recent buys at $6‑$7 and large sale at $44 signal confidence amid a 31% rally, hinting at future upside.

Insider buys by Long Daniel D. boost confidence in Septerna’s rising stock and pipeline, highlighting disciplined 10b5‑1 trading amid a strong rally.

Inside Septerna’s July 1 Form 4: Long Daniel D. buys low, sells high, signaling insider confidence amid a 213% YTD surge and growing drug pipeline.

Daniel Long’s recent buy‑sell moves at Septerna reveal insider confidence, with strategic gains amid a rising drug‑discovery pipeline and potential liquidity event.